Tianjin Medical University Second Hospital clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 1 with a minor change only.

1. Notable

   Is Prolonged Systemic Immunotherapy Necessary After Achieving…Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status · Extensive Transurethrally Unresectable Very-high-risk NMIBC?

   Recruitment opened

   Tianjin Medical University Second Hospital·Phase 2· NCT07625527· Registry history of NCT07625527 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

2. Notable

   Active Surveillance Versus Adjuvant Intravesical Chemotherapy in…Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC

   Recruitment opened

   Tianjin Medical University Second Hospital·Not applicable· NCT07749924· Registry history of NCT07749924 on ClinicalTrials.gov (opens the registry)

   Oct 9, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.